Li Junhua, Zhang Zhuangzhuang, Li Jing, Cun Ju-E, Pan Qingqing, Gao Wenxia, Luo Kui, He Bin, Gu Zhongwei, Pu Yuji
National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Wangjiang Road 29, Chengdu 610064, China.
School of Preclinical Medicine, Chengdu University, Chengdu 610106, China.
Acta Biomater. 2022 Oct 15;152:495-506. doi: 10.1016/j.actbio.2022.08.076. Epub 2022 Sep 8.
Despite the extensive explorations of nanoscale metal-organic frameworks (nanoMOFs) in drug delivery, the intrinsic bioactivity of nanoMOFs, such as anticancer activity, is severely underestimated owing to the overlooked integration of the hierarchical components including nanosized MOFs and molecular-level organic ligands and metal-organic complexes. Herein, we propose a de novo design of multifunctional bioactive nanoMOFs ranging from molecular to nanoscale level, and demonstrate this proof-of-concept by a copper-olsalazine (Olsa, a clinically approved drug for inflammatory bowel disease, here as a bioactive linker and DNA hypomethylating agent) nanoMOF displaying a multifaceted anticancer mechanism: (1) Cu-Olsa nanoMOF-mediated redox dyshomeostasis for enhanced catalytic tumor therapy, (2) targeting downregulation of cyclooxygenase-2 by the organic complex of Cu and Olsa, and (3) Olsa-mediated epigenetic regulation. Cu-Olsa nanoMOF displayed an enzyme-like catalytic activity to generate cancericidal species ·OH and O from rich HO in tumors, improved the expression of tumor suppressors TIMP3 and AXIN2 by epigenetic modulation, and fulfilled selective inhibition of colorectal cancer cells over normal cells. The hyaluronic acid-modified nanoMOF further verified the efficient suppression of CT26 colorectal tumor growth and metastasis in murine models. Overall, these results suggest that Olsa-based MOF presents a platform of epigenetic therapy-synergized nanomedicine for efficient cancer treatment and provides a powerful strategy for the design of intrinsically bioactive nanoMOFs. STATEMENT OF SIGNIFICANCE: Metal-organic frameworks (MOFs) with intrinsic bioactivities such as anticancer and antibacterial activity are of great interest. Herein, we reported a bioactive copper-olsalazine (Cu-Olsa) nanoMOF as a nanodrug for colorectal cancer treatment. This nanoMOF per se displayed enzyme-like catalytic activity to generate cancericidal species ·OH and O from rich HO in tumors for nanocatalytic tumor therapy. Upon dissociation into small molecular copper-organic complex and olsalazine in cancer cells, COX-2 inhibition and epigenetic modulation were fulfilled for selective inhibition of colorectal cancer growth and metastasis.
尽管纳米级金属有机框架(nanoMOF)在药物递送方面已得到广泛研究,但由于包括纳米尺寸的金属有机框架以及分子水平的有机配体和金属有机配合物在内的分级组件的整合被忽视,nanoMOF的内在生物活性,如抗癌活性,被严重低估。在此,我们提出了一种从分子到纳米尺度的多功能生物活性nanoMOF的从头设计,并通过一种铜-奥沙拉嗪(Olsa,一种临床上批准用于治疗炎症性肠病的药物,在此作为生物活性连接体和DNA去甲基化剂)纳米金属有机框架来证明这一概念验证,该纳米金属有机框架展示了多方面的抗癌机制:(1)Cu-Olsa纳米金属有机框架介导的氧化还原稳态失衡以增强催化肿瘤治疗,(2)通过Cu和Olsa的有机配合物靶向下调环氧合酶-2,以及(3)Olsa介导的表观遗传调控。Cu-Olsa纳米金属有机框架表现出类似酶的催化活性,可从肿瘤中丰富的H₂O₂生成杀癌物质·OH和O₂,通过表观遗传调控改善肿瘤抑制因子TIMP3和AXIN2的表达,并实现对结肠癌细胞相对于正常细胞的选择性抑制。透明质酸修饰的纳米金属有机框架进一步验证了在小鼠模型中对CT26结肠肿瘤生长和转移的有效抑制。总体而言,这些结果表明基于Olsa的金属有机框架为高效癌症治疗提供了一个表观遗传治疗协同纳米药物的平台,并为设计具有内在生物活性的纳米金属有机框架提供了有力策略。重要性声明:具有抗癌和抗菌活性等内在生物活性的金属有机框架(MOF)备受关注。在此,我们报道了一种生物活性铜-奥沙拉嗪(Cu-Olsa)纳米金属有机框架作为治疗结肠癌的纳米药物。这种纳米金属有机框架本身表现出类似酶的催化活性,可从肿瘤中丰富的H₂O₂生成杀癌物质·OH和O₂用于纳米催化肿瘤治疗。在癌细胞中解离成小分子铜-有机配合物和奥沙拉嗪后,实现了对环氧合酶-2的抑制和表观遗传调控,以选择性抑制结肠癌细胞的生长和转移。